MCID: CYS014
MIFTS: 51

Cystadenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Cystadenocarcinoma

MalaCards integrated aliases for Cystadenocarcinoma:

Name: Cystadenocarcinoma 12 54 43 15 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:3111
MeSH 43 D003536
NCIt 49 C2971
SNOMED-CT 67 21008007
UMLS 71 C0010631

Summaries for Cystadenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, in which cystic accumulations of retained secretions are formed.

MalaCards based summary : Cystadenocarcinoma is related to pancreatic serous cystadenocarcinoma and bile duct cystadenocarcinoma. An important gene associated with Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and Innate Immune System. The drugs Lenograstim and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include pancreas, ovary and liver, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Cystadenocarcinoma is a malignant form of a cystadenoma and is a cancer derived from glandular... more...

Related Diseases for Cystadenocarcinoma

Diseases related to Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 636)
# Related Disease Score Top Affiliating Genes
1 pancreatic serous cystadenocarcinoma 34.7 KRT7 CEACAM5
2 bile duct cystadenocarcinoma 34.5 MUC1 KRT7 CEACAM5
3 mucinous cystadenocarcinoma 34.3 VIM MUC2 MUC16 MUC1 KRT7 CEACAM5
4 ovarian cystadenocarcinoma 33.8 ZNF217 TP53 PIK3CA MUC16 MUC1 HRAS
5 appendix adenocarcinoma 33.4 KRT7 HRAS CEACAM5
6 serous cystadenocarcinoma 33.2 ZNF217 VEGFA TP53 PPP2R1A PIK3CA PGR
7 ovarian serous cystadenocarcinoma 32.6 ZNF217 VEGFA TP53 PPP2R1A PIK3CA PGR
8 papillary serous adenocarcinoma 32.5 TP53 PGR KRT7 CEACAM5
9 cystadenoma 31.8 PGR MUC16 MUC1 KRT7 CEACAM5 CEACAM3
10 cystic teratoma 31.3 TP53 MUC16 KRT7 CEACAM5
11 adenoma 31.3 TP53 PIK3CA MUC1 KRT7 BRAF
12 intrahepatic cholangiocarcinoma 31.2 TP53 MUC1 KRT7 ERBB2
13 teratoma 31.2 VIM TP53 KRT7 CEACAM5 AKT1
14 pseudomyxoma peritonei 31.2 TP53 MUC2 MUC16 MUC1 KRT7 CEACAM5
15 krukenberg carcinoma 31.1 MUC1 KRT7 CEACAM5
16 appendiceal neoplasm 31.0 KRT7 HRAS CEACAM5
17 spindle cell sarcoma 30.9 VIM VEGFA MUC1 KRT7
18 benign teratoma 30.9 TP53 MUC1 KRT7 CEACAM5
19 ovarian cystadenoma 30.9 TP53 MUC16 KRT7 CEACAM5
20 papillary carcinoma 30.9 PGR MUC1 KRT7 ERBB2 BRAF
21 small cell carcinoma 30.8 TP53 MUC1 KRT7
22 polymorphous low-grade adenocarcinoma 30.8 VIM MUC1 CEACAM3
23 bile duct cysts 30.8 KRT7 HRAS CEACAM5
24 mucinous adenocarcinoma 30.7 VIM VEGFA TP53 PGR MUC16 MUC1
25 papillary adenocarcinoma 30.7 VIM TP53 PGR MUC16 MUC1 KRT7
26 intestinal obstruction 30.7 VEGFA KRT7 CEACAM5
27 mucoepidermoid carcinoma 30.7 TP53 MUC2 MUC1 KRT7 ERBB2 CEACAM5
28 urachal adenocarcinoma 30.7 CEACAM5 BRAF
29 angiosarcoma 30.7 VIM VEGFA TP53 MUC1 KRT7
30 myoma 30.7 TP53 PGR MUC16
31 cervical squamous cell carcinoma 30.7 VEGFA TP53 PIK3CA AKT1
32 rhabdoid tumor predisposition syndrome 1 30.7 VIM TP53 MUC1
33 adenocarcinoma 30.7 VEGFA TP53 PIK3CA MUC1 KRT7 HRAS
34 villous adenoma 30.7 TP53 MUC1 HRAS CEACAM5 BRAF
35 ovarian carcinosarcoma 30.6 TP53 PPP2R1A PIK3CA ERBB2
36 uterine corpus endometrial carcinoma 30.6 TP53 PPP2R1A PIK3CA HRAS
37 pleomorphic adenoma 30.6 VIM TP53 MUC1 KRT7 HRAS ERBB2
38 mature teratoma 30.6 TP53 NANOG KRT7 ERBB2 CEACAM5 BRAF
39 polycystic liver disease 1 with or without kidney cysts 30.6 MUC16 MUC1 KRT7 CEACAM5 CEACAM3
40 endometriosis 30.6 VEGFA TP53 PGR MUC16
41 cavernous hemangioma 30.6 VIM VEGFA MUC1 KRT7
42 appendix cancer 30.6 TP53 MUC1 KRT7 HRAS CEACAM5
43 in situ carcinoma 30.6 TP53 PIK3CA PGR MUC1 HRAS ERBB2
44 breast fibroadenoma 30.6 TP53 PGR ERBB2
45 sclerosing hemangioma 30.6 PGR MUC1 KRT7
46 hemangioma 30.6 VEGFA TP53 PGR MUC1 KRT7 AKT1
47 clear cell adenocarcinoma 30.5 TP53 PIK3CA MUC16 KRT7
48 ovarian mucinous adenocarcinoma 30.5 MUC2 KRT7 CEACAM5
49 pancreatic ductal adenocarcinoma 30.5 VEGFA TP53 MUC1 ERBB2 AKT1
50 mucinous ovarian cystadenoma 30.5 KRT7 CEACAM5

Graphical network of the top 20 diseases related to Cystadenocarcinoma:



Diseases related to Cystadenocarcinoma

Symptoms & Phenotypes for Cystadenocarcinoma

GenomeRNAi Phenotypes related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.62 BRAF HRAS MUC1 PIK3CA
2 Decreased viability GR00055-A-2 9.62 BRAF HRAS MUC1 PIK3CA
3 Decreased viability GR00221-A-1 9.62 HRAS PIK3CA
4 Decreased viability GR00221-A-2 9.62 HRAS PIK3CA
5 Decreased viability GR00221-A-3 9.62 HRAS
6 Decreased viability GR00221-A-4 9.62 BRAF PIK3CA
7 Decreased viability GR00249-S 9.62 BRAF MUC1
8 Decreased viability GR00301-A 9.62 BRAF
9 Decreased viability GR00381-A-1 9.62 BRAF
10 Decreased viability GR00402-S-2 9.62 PIK3CA
11 Decreased cell migration GR00055-A-1 9.35 AKT1 VIM
12 Decreased cell migration GR00055-A-3 9.35 BRAF HRAS PIK3CA

MGI Mouse Phenotypes related to Cystadenocarcinoma:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 AKT1 B2M BRAF ERBB2 FBXW7 KRT7
2 cardiovascular system MP:0005385 10.29 AKT1 B2M BRAF ERBB2 FBXW7 HRAS
3 homeostasis/metabolism MP:0005376 10.25 AKT1 B2M BRAF ERBB2 FBXW7 HRAS
4 embryo MP:0005380 10.2 AKT1 B2M BRAF ERBB2 FBXW7 NANOG
5 endocrine/exocrine gland MP:0005379 10.17 AKT1 B2M BRAF ERBB2 FBXW7 HRAS
6 mortality/aging MP:0010768 10.17 AKT1 B2M BRAF ERBB2 FBXW7 HRAS
7 digestive/alimentary MP:0005381 10.08 B2M BRAF ERBB2 FBXW7 HRAS MUC2
8 integument MP:0010771 10.07 AKT1 B2M BRAF ERBB2 FBXW7 HRAS
9 neoplasm MP:0002006 9.93 AKT1 B2M BRAF ERBB2 FBXW7 HRAS
10 muscle MP:0005369 9.86 AKT1 BRAF ERBB2 PGR PIK3CA TP53
11 normal MP:0002873 9.61 AKT1 BRAF ERBB2 FBXW7 HRAS PGR
12 respiratory system MP:0005388 9.23 AKT1 BRAF ERBB2 FBXW7 HRAS TP53

Drugs & Therapeutics for Cystadenocarcinoma

Drugs for Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 209)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3 135968-09-1
2
Everolimus Approved Phase 2, Phase 3 159351-69-6 70789204 6442177
3
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
4
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
5
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
6
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
7
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
8
leucovorin Approved Phase 3 58-05-9 6006 143
9
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
10
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054
11
Fluorouracil Approved Phase 3 51-21-8 3385
12
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
13
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
14
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
15
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
16
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
17
Cisplatin Approved Phase 2, Phase 3 15663-27-1 2767 441203 84093
18
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
19
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
20
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
21
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
22
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
23
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
24
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
25
Pembrolizumab Approved Phase 3 1374853-91-4
26
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
27
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
28
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
29
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
30
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
31 Edrecolomab Experimental, Investigational Phase 3 156586-89-9
32
Camptothecin Experimental Phase 3 7689-03-4
33
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
34
Maleic acid Experimental, Investigational Phase 2, Phase 3 110-17-8, 110-16-7 444972
35 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
36 Adjuvants, Immunologic Phase 3
37 Formyltetrahydrofolates Phase 3
38 Tetrahydrofolates Phase 3
39 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3
40 Carotenoids Phase 3
41 Antimetabolites Phase 3
42 topoisomerase I inhibitors Phase 2, Phase 3
43 Hormone Antagonists Phase 2, Phase 3
44 Hormones Phase 3
45 Estrogen Antagonists Phase 2, Phase 3
46 Estrogen Receptor Antagonists Phase 2, Phase 3
47 Immunosuppressive Agents Phase 3
48 Estrogens Phase 2, Phase 3
49 Aromatase Inhibitors Phase 2, Phase 3
50 Antineoplastic Agents, Hormonal Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 207)
# Name Status NCT ID Phase Drugs
1 A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA Completed NCT00002568 Phase 3 cisplatin;paclitaxel
2 CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Completed NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
3 A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma Completed NCT00003644 Phase 3 carboplatin;paclitaxel
4 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
5 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
6 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
7 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
8 A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
9 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
10 Phase III Randomized Study of Adjuvant Immunotherapy With Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for State II (Modified Astler-Coller B2) Adenocarcinoma of the Colon Completed NCT00002968 Phase 3
11 Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
12 Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
13 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Recruiting NCT03422198 Phase 3
14 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Recruiting NCT04095364 Phase 3 Carboplatin;Letrozole;Paclitaxel
15 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Recruiting NCT00719303 Phase 3
16 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
17 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
18 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
19 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
20 A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
21 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
22 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
23 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
24 A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
25 A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen;Tamoxifen Citrate;Topotecan;Topotecan Hydrochloride;Trametinib;Trametinib Dimethyl Sulfoxide
26 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
27 Randomized Phase II/III Trial to Assess the Efficacy of Platinum-based Chemotherapy vs Standard Non-platinum Therapy in Patients With Platinum-resistant Recurrent Ovarian Cancer (ROC) Not yet recruiting NCT04055038 Phase 2, Phase 3 Platinum-Based Drug;Conventional chemotherapy
28 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Suspended NCT03914612 Phase 3 Carboplatin;Paclitaxel
29 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
30 A Phase II/III Trial of Chemotherapy Alone Versus Chemotherapy Plus SCH 58500 in Newly Diagnosed Stage III Ovarian and Primary Peritoneal Cancer Patients With Greater Than or Equal to 0.5 cm and Less Than or Equal to 2 cm Residual Disease Following Surgery Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
31 A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO PRIMARY THERAPY Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
32 A Randomized, Double-Blinded, Placebo Controlled Phase III Trial Using Acetyl-L-Carnitine(ALC)(NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Withdrawn NCT01492920 Phase 3
33 A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
34 A Phase II Study of TLK 286 in Platinum Resistant Advanced Epithelial Ovarian Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
35 LAPAROSCOPIC STAGING IN PATIENTS WITH INCOMPLETELY STAGED CANCERS OF THE OVARY Completed NCT00002538 Phase 2
36 A Phase II Evaluation of Belinostat (NSC #726630) and Carboplatin (NSC #241240) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00993616 Phase 2 belinostat;carboplatin
37 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
38 A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Suboptimally Debulked Stage III or IV Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
39 A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas Completed NCT02283658 Phase 2 Everolimus;Letrozole
40 Phase II Evaluation Of Neoadjuvant Chemotherapy, Interval Debulking Followed By Intraperitoneal Chemotherapy In Women With Stage III And IV Epithelial Ovarian Cancer, Fallopian Tube Cancer Or Primary Peritoneal Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
41 Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
42 A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00939809 Phase 2
43 A Phase I-II Study of OSI-774 (Tarceva, Erlotinib) With Docetaxel/Carboplatin Followed by Maintenance Therapy With Tarceva as Treatment for Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
44 A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxane™) as Chemoimmunotherapy for Platinum-Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
45 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
46 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
47 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
48 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
49 A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma Completed NCT00025467 Phase 2 thalidomide
50 A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma Completed NCT00478426 Phase 2 Sunitinib Malate

Search NIH Clinical Center for Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma

Genetic Tests for Cystadenocarcinoma

Anatomical Context for Cystadenocarcinoma

MalaCards organs/tissues related to Cystadenocarcinoma:

40
Pancreas, Ovary, Liver, Appendix, Breast, Salivary Gland, Colon

Publications for Cystadenocarcinoma

Articles related to Cystadenocarcinoma:

(show top 50) (show all 2270)
# Title Authors PMID Year
1
Role of cystic fluid in diagnosis of the pancreatic cystadenoma and cystadenocarcinoma. 61 54
18251127 2007
2
Improved early diagnosis of cystadenocarcinoma of the pancreas. 54 61
17287173 2007
3
Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. 61 54
10573510 1999
4
Immunohistochemical demonstration of nonspecific cross-reacting antigen in normal and neoplastic human tissues using a monoclonal antibody. Comparison with carcinoembryonic antigen localization. 54 61
2187320 1990
5
Measurement of CA125, carcinoembryonic antigen, and alpha-fetoprotein in ovarian cyst fluid: diagnostic adjunct to cytology. 54 61
1696873 1990
6
Cystadenocarcinoma of the pancreas: neo-adjuvant therapy and CEA monitoring. 61 54
2296199 1990
7
Chemoresistance-associated alternative splicing signatures in serous ovarian cancer. 61
32565967 2020
8
Survey and comparative assessments of computational multi-omics integrative methods with multiple regulatory networks identifying distinct tumor compositions across pan-cancer data sets. 61
32533167 2020
9
Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family. 61
32356124 2020
10
Sunitinib as Successful Maintenance Therapy for Recurrent Pancreatic Serous Cystadenocarcinoma. 61
32541193 2020
11
Ancestry-specific predisposing germline variants in cancer. 61
32471518 2020
12
A comprehensive analysis of IDO1 expression with tumour-infiltrating immune cells and mutation burden in gynaecologic and breast cancers. 61
32227579 2020
13
Distant metastasis from oral cavity-correlation between histopathology results and primary site. 61
32468449 2020
14
A Rare Case of Incidental Urachal Mucinous Cystadenocarcinoma. 61
32523832 2020
15
A common variant rs2272804 in the 5'UTR of RIBC2 inhibits downstream gene expression by creating an upstream open reading frame. 61
32329860 2020
16
Serous Microcystic Cystadenocarcinoma of the Pancreas with Synchronous Liver Metastases: Clinical Characteristics and Management. 61
32431986 2020
17
Humeral air sac cystadenocarcinoma in a rainbow lorikeet (Trichoglossus moluccanus). 61
32017026 2020
18
Characterization of Black Pigmenturia in a Cat with Apocrine Gland Cystadenocarcinoma. 61
32359628 2020
19
The androgen receptor expression and association with patient's survival in different cancers. 61
31759122 2020
20
Primary malignant pericardial tumour in Lynch syndrome. 61
32143595 2020
21
Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma. 61
32105524 2020
22
Changes in the Concentration of Markers Participating in the Regulation of the Apoptosis Receptor Pathway Involving Soluble Tumour Necrosis Factor Ligand inducing Apoptosis (sTRAIL) and Osteoprotegerin (OPG) in the Serum of Women with Ovarian Cancer-Participation in Pathogenesis or a Possible Clinical Use? 61
32143328 2020
23
Histopathological evaluation of minor salivary gland papillary-cystic tumours: focus on genetic alterations in sialadenoma papilliferum and intraductal papillary mucinous neoplasm. 61
31505033 2020
24
18F-FDG PET/CT Findings in a Patient With Primary Mucinous Cystadenocarcinoma of the Breast. 61
31876834 2020
25
Incidental detection of microfilaria in cyst fluid of Mucinous cystadenocarcinoma of ovary: A rare case report. 61
32416487 2020
26
Low-grade Apocrine Intraductal Carcinoma: Expanding the Morphologic and Molecular Spectrum of an Enigmatic Salivary Gland Tumor. 61
31989433 2020
27
Comprehensive analysis of LDHAP5 pseudogene expression and potential pathogenesis in ovarian serous cystadenocarcinoma. 61
32536817 2020
28
A rare missense variant in APC interrupts splicing and causes AFAP in two Danish families. 61
32292534 2020
29
Pan-cancer diagnostic consensus through searching archival histopathology images using artificial intelligence. 61
32195366 2020
30
OTUD4: A Potential Prognosis Biomarker for Multiple Human Cancers. 61
32184655 2020
31
Dynamic TF-lncRNA Regulatory Networks Revealed Prognostic Signatures in the Development of Ovarian Cancer. 61
32478062 2020
32
Role of Cross-sectional Imaging (CT/MRI) in Characterization and Distinguishing Benign from Malignant/Potentially Malignant Cystic Lesions of Pancreas. 61
32494507 2020
33
Surgery for cystic tumors of pancreas: Report of high-volume, multicenter Indian experience over a decade. 61
31543321 2019
34
Proceedings of the 2019 National Toxicology Program Satellite Symposium. 61
31645210 2019
35
Surveillance and management for serous cystic neoplasms of the pancreas based on total hazards-a multi-center retrospective study from China. 61
32042823 2019
36
A Novel Scoring System for Pivotal Autophagy-Related Genes Predicts Outcomes after Chemotherapy in Advanced Ovarian Cancer Patients. 61
31533939 2019
37
[A Case of Mucinous Cystoadenocarcinoma with Metastatic Liver Tumor in a Young Woman Lacking Specific Findings]. 61
32156954 2019
38
Identification of hub genes and key pathways associated with the progression of gynecological cancer. 61
31788113 2019
39
[Spectrum analysis of pathological classification in 463 cases with nasal and paranasal sinuses malignant tumors]. 61
31914269 2019
40
[Appendix Cancer with Long-Term Survival after Multimodality Therapy-A Case Report]. 61
32156998 2019
41
Interpretable deep neural network for cancer survival analysis by integrating genomic and clinical data. 61
31865908 2019
42
Metastatic mucinous cystadenocarcinoma of the pancreas presenting as intractable back pain. 61
31791983 2019
43
CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress. 61
31766991 2019
44
A comprehensive understanding of ovarian carcinoma survival prognosis by novel biomarkers. 61
31646556 2019
45
Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA. 61
31607216 2019
46
NCOA4-RET and TRIM27-RET Are Characteristic Gene Fusions in Salivary Intraductal Carcinoma, Including Invasive and Metastatic Tumors: Is "Intraductal" Correct? 61
31162284 2019
47
Laparoscopic right colectomy associated with hyperthermic intraperitoneal chemotherapy as treatment for mucinous cystadenocarcinoma of the appendix - a video vignette. 61
31309644 2019
48
Identification of a 3-mRNA signature as a novel potential prognostic biomarker in patients with ovarian serous cystadenocarcinoma in G2 and G3. 61
31579405 2019
49
Impact of routine histopathological examination of appendectomy specimens on patient management: a study of 4012 appendectomy specimens. 61
32550328 2019
50
Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study. 61
31491988 2019

Variations for Cystadenocarcinoma

Expression for Cystadenocarcinoma

Search GEO for disease gene expression data for Cystadenocarcinoma.

Pathways for Cystadenocarcinoma

Pathways related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 VIM VEGFA TP53 PPP2R1A MUC1 HRAS
2
Show member pathways
13.75 VIM VEGFA TP53 PPP2R1A PIK3CA NANOG
3
Show member pathways
13.71 PPP2R1A PIK3CA MUC2 MUC16 MUC1 HRAS
4
Show member pathways
13.61 VEGFA TP53 PPP2R1A PIK3CA HRAS ERBB2
5
Show member pathways
13.56 VEGFA PPP2R1A PIK3CA NANOG KRT7 HRAS
6
Show member pathways
13.53 TP53 PPP2R1A PIK3CA HRAS FBXW7 ERBB2
7
Show member pathways
13.38 VEGFA TP53 PPP2R1A PIK3CA HRAS CEACAM5
8
Show member pathways
13.33 VIM VEGFA PPP2R1A NANOG HRAS ERBB2
9
Show member pathways
13.13 TP53 PPP2R1A PIK3CA HRAS BRAF AKT1
10
Show member pathways
13.04 VIM VEGFA TP53 PPP2R1A PIK3CA NANOG
11
Show member pathways
13.03 VEGFA TP53 PPP2R1A PIK3CA HRAS ERBB2
12
Show member pathways
13.02 VEGFA TP53 PIK3CA HRAS B2M AKT1
13
Show member pathways
12.98 VEGFA PIK3CA HRAS ERBB2 BRAF AKT1
14
Show member pathways
12.97 VEGFA PIK3CA HRAS ERBB2 BRAF AKT1
15
Show member pathways
12.88 VIM TP53 PIK3CA B2M AKT1
16
Show member pathways
12.87 VEGFA TP53 PIK3CA HRAS ERBB2 BRAF
17 12.84 VEGFA TP53 PIK3CA HRAS ERBB2 BRAF
18 12.83 VEGFA TP53 HRAS ERBB2 BRAF AKT1
19
Show member pathways
12.81 VEGFA PIK3CA HRAS BRAF AKT1
20
Show member pathways
12.78 TP53 PPP2R1A PIK3CA HRAS ERBB2 AKT1
21
Show member pathways
12.77 TP53 PIK3CA HRAS ERBB2 BRAF AKT1
22
Show member pathways
12.75 VEGFA PIK3CA PGR HRAS AKT1
23
Show member pathways
12.74 TP53 PPP2R1A HRAS BRAF AKT1
24
Show member pathways
12.71 TP53 PIK3CA HRAS ERBB2 BRAF AKT1
25
Show member pathways
12.66 TP53 PIK3CA HRAS ERBB2 AKT1
26
Show member pathways
12.64 TP53 PIK3CA PGR MUC2 HRAS ERBB2
27
Show member pathways
12.58 VEGFA TP53 PIK3CA HRAS ERBB2 BRAF
28
Show member pathways
12.57 TP53 PPP2R1A PIK3CA HRAS AKT1
29 12.54 VIM VEGFA TP53 PIK3CA HRAS ERBB2
30
Show member pathways
12.52 TP53 PIK3CA HRAS ERBB2 AKT1
31
Show member pathways
12.5 TP53 PIK3CA HRAS ERBB2 BRAF AKT1
32
Show member pathways
12.49 VEGFA TP53 PIK3CA MUC1 HRAS AKT1
33
Show member pathways
12.47 PIK3CA HRAS BRAF AKT1
34
Show member pathways
12.47 VEGFA PIK3CA HRAS BRAF AKT1
35
Show member pathways
12.46 TP53 PIK3CA HRAS AKT1
36
Show member pathways
12.42 PPP2R1A PIK3CA PGR BRAF AKT1
37
Show member pathways
12.39 PIK3CA HRAS ERBB2 AKT1
38
Show member pathways
12.39 PIK3CA HRAS ERBB2 AKT1
39 12.39 TP53 PIK3CA HRAS B2M AKT1
40
Show member pathways
12.36 TP53 PIK3CA HRAS ERBB2 AKT1
41
Show member pathways
12.35 PPP2R1A PIK3CA HRAS BRAF
42
Show member pathways
12.33 VEGFA TP53 HRAS BRAF AKT1
43
Show member pathways
12.31 PIK3CA HRAS CEACAM5 CEACAM3
44 12.27 VEGFA TP53 BRAF AKT1
45 12.27 HRAS ERBB2 BRAF AKT1
46
Show member pathways
12.25 TP53 PIK3CA HRAS ERBB2 BRAF AKT1
47 12.24 TP53 PIK3CA HRAS AKT1
48 12.23 VEGFA TP53 BRAF AKT1
49
Show member pathways
12.23 PIK3CA MUC1 HRAS ERBB2 BRAF AKT1
50
Show member pathways
12.22 TP53 HRAS BRAF AKT1

GO Terms for Cystadenocarcinoma

Cellular components related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.44 VIM PPP2R1A PIK3CA MUC2 MUC16 MUC1

Biological processes related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.76 VEGFA HRAS ERBB2 AKT1
2 positive regulation of epithelial cell proliferation GO:0050679 9.7 VEGFA HRAS ERBB2
3 positive regulation of MAP kinase activity GO:0043406 9.69 VEGFA HRAS ERBB2
4 O-glycan processing GO:0016266 9.65 MUC2 MUC16 MUC1
5 negative regulation of gene expression GO:0010629 9.63 VEGFA TP53 PGR HRAS FBXW7 AKT1
6 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.62 MUC2 MUC16 MUC1 HRAS
7 epidermal growth factor receptor signaling pathway GO:0007173 9.58 PIK3CA BRAF AKT1
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.56 VEGFA PIK3CA BRAF AKT1
9 anoikis GO:0043276 9.54 PIK3CA AKT1
10 phosphatidylinositol 3-kinase signaling GO:0014065 9.54 PIK3CA ERBB2 AKT1
11 positive regulation of gene expression GO:0010628 9.5 VIM VEGFA TP53 HRAS ERBB2 BRAF
12 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.49 TP53 MUC1
13 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.43 VEGFA TP53
14 cytokine-mediated signaling pathway GO:0019221 9.17 VIM VEGFA TP53 PIK3CA NANOG MUC1

Molecular functions related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 ZNF217 VIM VEGFA TP53 PPP2R1A PIK3CA
2 identical protein binding GO:0042802 9.32 VIM VEGFA TP53 PGR FBXW7 ERBB2

Sources for Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....